AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Strensiq (asfotase alfa) by Year
Strensiq (asfotase alfa) — Worldwide product sales ($M) ($M)
AstraZeneca Strensiq (asfotase alfa): $1,678M in FY2025, up 18.5% from a year earlier.
Where the FY2025 figure comes from
“|| Strensiq | 1,678 | 19 | 18 | 1,332 | 14 | 104 | 94 | 84 | 123 | 25 | 21 | 119 | 23 | 23”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Strensiq (asfotase alfa) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,678 | +18.5% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 1,416 | +22.9% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 1,152 | +20.3% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 958 | +153.4% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 378 | – | Form 6-K FY2021Q4 Earnings Release ↗ |
Breakdown
What makes up strensiq (asfotase alfa)
- Strensiq (asfotase alfa) — Worldwide YoY actual (%)19.0% · FY2025
- Strensiq (asfotase alfa) — Worldwide YoY CER (%)18.0% · FY2025
- Strensiq (asfotase alfa) — US product sales ($M)1,332 · FY2025
- Strensiq (asfotase alfa) — Emerging Markets product sales ($M)104 · FY2025
- Strensiq (asfotase alfa) — Europe product sales ($M)123 · FY2025
- Strensiq (asfotase alfa) — Established RoW product sales ($M)119 · FY2025
Cite this data
StockData. (2026). AstraZeneca Strensiq (asfotase alfa) ($M), annual FY2021–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-strensiq-world
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.